https://orcid.org/0000-0001-6233-1225
References
- Heckmann X, Lambert V, Mion G, et al. Failure of a Mexican antivenom on recovery from snakebite-related coagulopathy in French Guiana. Clin Toxicol. 2020;0(0):1–7.
- Bollaert J, Annane D, Aube H, et al. Coagulations intravasculaires disséminées (CIVD) en réanimation: définition, classification et traitement (à l’exception des cancers et hémopathies malignes). Réanimation. 2002;11(8):567–574.
- Otero-Patiño R, Silva-Haad JJ, Acevedo B, et al. Accidente bothrópico en Colombia: estudio multicéntrico de la eficacia seguridad de Antivipmyn-Tri®, un antiveneno polivalente producido en México. IATREIA. 2007;20(3):244–262.
- Steinhoff S. LD50 of venomous snakes [Internet]. the Snake Database. 2016. [cited 2016 Dec 5]. Available from: http://snakedatabase.org/pages/LD50.php.
- World Health Organization. WHO guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva: WHO Press; 2010.
- Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. Pediatrics. 1957;19(5):823–832.
- Maduwage K, Buckley NA, de Silva HJ, et al. Snake antivenom for snake venom induced consumption coagulopathy. Cochrane Database Syst Rev. 2015;(6):CD011428.